Shirai et al. reported nuclear survivin expression to be a poor prognosis predictor in GBM [79], while Saito and colleagues reported that the simultaneous expression of survivin in the nucleus and in the cytoplasm correlated with a poor prognosis in high-grade astrocytoma, including GBM [80]. This evidence concerns the gene BIRC5 and astrocytoma (excluding glioblastoma).